Iterum Therapeutics Files for Winding Up in Ireland, Appoints Liquidators, CEO/CFO Resign
ITRM sits 32% above its 52-week low of $0.136 on light trading volume (0.3× avg).
Summary
Iterum Therapeutics plc has filed a petition to wind up the company in Ireland, leading to the appointment of provisional liquidators, the resignation of its CEO and CFO, and a warning of potential complete loss for shareholders.
Key Events · Legal and Risk Events · ITRM
-
Company Files for Winding Up
Iterum Therapeutics plc filed a petition in the High Court in Ireland on March 27, 2026, to wind up the company, with a hearing scheduled for April 13, 2026. If approved, this will lead to the company's ultimate dissolution.
-
Joint Provisional Liquidators Appointed
Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited were appointed as Joint Provisional Liquidators, immediately assuming executive authority.
-
CEO and CFO Resign
Corey Fishman, President and CEO, and Judith Matthews, CFO, resigned from their positions effective immediately following the winding up petition filing.
-
Debt Default Triggered
The winding up petition constitutes an event of default under the company's Royalty-Linked Subordinated Notes, leading to increased interest accrual and allowing noteholders to sue for outstanding principal and accrued default interest.
Analysis · ITRM · Life Sciences
Iterum Therapeutics plc has initiated formal winding-up proceedings in Ireland, a critical step towards the company's dissolution. This action triggers an event of default on its royalty-linked notes, leading to increased interest accrual and potential legal action from noteholders. The immediate resignation of the CEO and CFO, coupled with the transfer of executive authority to provisional liquidators, underscores the finality of this decision. The company explicitly warns shareholders of a significant or complete loss on their investment and anticipates delisting from Nasdaq, signaling the end of its public trading. Investors should consider this a definitive and highly negative development.
At the time of this filing, ITRM was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $0.14 to $1.42. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.